1. FK 506 reduces tissue damage and prevents functional deficit after spinal cord injury in the rat.
- Author
-
López-Vales R, García-Alías G, Forés J, Udina E, Gold BG, Navarro X, and Verdú E
- Subjects
- Animals, Anti-Inflammatory Agents pharmacology, Cyclooxygenase 2 biosynthesis, Electrophysiology, Female, Glial Fibrillary Acidic Protein biosynthesis, Gliosis pathology, Immunohistochemistry, Inflammation pathology, Interleukin-1 biosynthesis, Methylprednisolone pharmacology, Motor Activity drug effects, Motor Activity physiology, Nitric Oxide Synthase Type II biosynthesis, Rats, Rats, Sprague-Dawley, Spinal Cord Injuries pathology, Walking, Immunosuppressive Agents pharmacology, Neuroprotective Agents, Spinal Cord Injuries drug therapy, Spinal Cord Injuries physiopathology, Tacrolimus pharmacology
- Abstract
We examined the efficacy of FK 506 in reducing tissue damage after spinal cord injury in comparison to methylprednisolone (MP) treatment. Rats were subjected to a photochemical injury (T8) and were given a bolus of MP (30 mg/kg), FK 506 (2 mg/kg), or saline. An additional group received an initial bolus of FK 506 (2 mg/kg) followed by daily injections (0.2 mg/kg intraperitoneally). Functional recovery was evaluated using open-field walking, inclined plane tests, motor evoked potentials (MEPs), and the H-reflex response during 14 days postoperation (dpo). Tissue sparing and glial fibrillary acidic protein (GFAP), biotinylated tomato lectin LEC, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and interleukin 1 beta (IL-1 beta) immunoreactivity were quantified in the injured spinal cord. FK 506-treated animals demonstrated significantly better neurologic outcome, higher MEP amplitudes, and lower H-wave amplitude compared to that of saline-treated rats. In contrast, administration of MP did not result in significant differences with respect to the saline-treated group. Histologic examination revealed that tissue sparing was largest in FK 506-treated compared to saline and MP-treated animals. GFAP and COX-2 reactivity was decreased in animals treated with FK 506 compared to that in animals given MP or saline, whereas IL-1 beta expression was similarly reduced in both FK 506- and MP-treated groups. Microglia/macrophage response was reduced in FK 506 and MP-injected animals at 3 dpo, but only in MP-treated animals at 7 dpo with respect to saline-injected rats. Repeated administrations of FK 506 improved functional and histologic results to a greater degree than did a single bolus of FK 506. The results indicate that FK 506 administration protects the damaged spinal cord and should be considered as potential therapy for treating spinal cord injuries.
- Published
- 2005
- Full Text
- View/download PDF